As previously reported, Scotiabank analyst George Farmer initiated coverage of Viking Therapeutics (VKTX) with an Outperform rating and $102 ...

Not all growth stocks worth buying these days focus on the artificial intelligence field. There are many exciting ones in ...

Viking Therapeutics (NASDAQ: VKTX) shares exploded higher after the clinical-stage drugmaker announced successful results ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

The results of the first head-to-head trial of Lilly's dual GLP-1/GIP agonist Zepbound (tirzepatide) and Novo Nordisk's GLP-1 agonist Wegovy (semaglutide) have shown experimentally what has been ...

Phase 2 stage CT-388, a dual GLP-1/GIP receptor agonist injected subcutaneously, CT-996, a Phase 1 stage oral, small molecule GLP-1 receptor agonist, and CT-868, a Phase-2, once-daily subcutaneous ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as GLP-1 receptor agonists, including the popular name brands Ozempic, Wegovy, ...

How much is Green Impact Partners Inc stock worth? Invest with precise valuations. Get Report.

Anaesthetists are also advised to “consider the potential risk of aspiration within their risk assessment of patients being treated with GLP-1 or dual glucose dependent insulinotropic peptide receptor ...

Share on Pinterest Zepbound is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) drug. You inject the drug into your stomach, thigh, or upper arm.